Aktienanalyse wird geladen …
Wir verwenden nur technisch notwendige Cookies (Anmeldung & Zahlung) — kein Tracking. Mehr dazu in der Datenschutzerklärung.
WTW · NMS · Insurance Agents, Brokers & Service
343,01 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw.) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 9,71 Mrd. | 1,61 Mrd. | 16,26 $ | 99 Mio. | 0,4 Mio · 0,5 % | 3,4 Mio · 3,5 % | — | 16,5 % | 15,62 $ | 1,55 $ | 3,68 $ |
| 2024 | 9,93 Mrd. | -98 Mio. | -0,96 $ | 102 Mio. | 0,4 Mio · 0,3 % | 4,4 Mio · 4,3 % | — | -1 % | 12,42 $ | 1,19 $ | 3,52 $ |
| 2023 | 9,48 Mrd. | 1,06 Mrd. | 9,95 $ | 106 Mio. | 0,4 Mio · 0,3 % | 6,4 Mio · 6 % | — | 11,1 % | 10,41 $ | 1,18 $ | 3,36 $ |
| 2022 | 8,87 Mrd. | 1,01 Mrd. | 8,98 $ | 112 Mio. | 0,3 Mio · 0,3 % | 17,3 Mio · 15,4 % | — | 11,4 % | — | 0,88 $ | 3,28 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,47 Mrd. | 229 Mio. | 2,31 $ | — | 9,3 % | 4,29 $ |
| Q1 2026 | 2,41 Mrd. | 297 Mio. | 3,00 $ | — | 12,3 % | -0,66 $ |
| Q4 2025 | 2,94 Mrd. | 735 Mio. | 7,42 $ | — | 25 % | 7,15 $ |
| Q3 2025 | 2,29 Mrd. | 304 Mio. | 3,07 $ | — | 13,3 % | 6,27 $ |
| Q2 2025 | 2,26 Mrd. | 331 Mio. | 3,34 $ | — | 14,6 % | 3,06 $ |
| Q1 2025 | 2,22 Mrd. | 235 Mio. | 2,37 $ | — | 10,6 % | -0,87 $ |
| Q4 2024 | 3,04 Mrd. | 1,25 Mrd. | 12,59 $ | — | 41,1 % | 5,48 $ |
| Q3 2024 | 2,29 Mrd. | -1,68 Mrd. | -16,92 $ | — | -73,2 % | 4,23 $ |
Raymond James Adjusts PT on Willis Towers Watson Public to $400 From $340, Keeps Strong Buy Rating
WTW Investments and SEI Partner to Expand Private Markets Solutions for Defined Contribution Plans
Jefferies Adjusts Price Target on Willis Towers Watson Public to $402 From $343, Maintains Buy Rating
Keefe, Bruyette & Woods Adjusts Price Target on Willis Towers Watson Public to $394 From $381, Maintains Outperform Rating
WTW 2026 Defined Contribution Survey: Employers face a retirement readiness gap, and pressure is mounting to prove plans work
UBS Adjusts Price Target on Willis Towers Watson Public to $405 From $382, Maintain Buy Rating
Autonomous Research Adjusts Price Target on Willis Towers Watson Public to $392 From $369, Maintain Outperform Rating
Goldman Sachs Adjusts Price Target on Willis Towers Watson Public to $385 From $316, Maintain Buy Rating
Melde dich an und teste Glancefield Pro 3 Tage gratis — inklusive dem fairen Wert von WTW und unbegrenzten Analysen.